Home/Recalls/FDA-D-0259-2026
FDA DrugsClass II

Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, Ma...

Published: January 21, 2026Recall ID: D-0259-2026Category: drugsCountry: US

Reason for Recall / Hazard

Product Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.

Product Description & Identification

Levothyroxine Sodium Tablets, USP, Thyro-Tabs, 150mcg, 1000 Tablets, Rx only, Manufactured by: LLOYD, Inc., Shenandoah, IA, 51601 USA, Distributed by: Alvogen, Inc., Pine Brook, NJ 07058 USA, NDC: 47781-662-10.

Additional Source Details

FieldValue
CityMorristown
StateNJ
Openfda › Upc › 10347781649906
Openfda › Upc › 20347781671907
Openfda › Upc › 30347781643904
Openfda › Upc › 40347781657901
Openfda › Upc › 50347781640903
Openfda › Upc › 60347781651909
Openfda › Upc › 70347781662905
Openfda › Upc › 80347781665906
Openfda › Upc › 90347781646905
Openfda › Upc › 100347781654900
Openfda › Upc › 110347781659905
Openfda › Unii9J765S329G
Openfda › RouteORAL
Openfda › Rxcui › 1892246
Openfda › Rxcui › 2892251
Openfda › Rxcui › 3892255
Openfda › Rxcui › 4966220
Openfda › Rxcui › 5966221
Openfda › Rxcui › 6966222
Openfda › Rxcui › 7966224
Openfda › Rxcui › 8966225
Openfda › Rxcui › 9966248
Openfda › Rxcui › 10966249
Openfda › Rxcui › 11966253
Openfda › Rxcui › 12966270
Openfda › Spl id12e236b4-dc71-96ce-cdd3-7bede41b3f1c
Openfda › Brand nameLEVOTHYROXINE SODIUM
Openfda › Spl set id4ddcaec1-a58f-340b-9bc1-bbe048b8c885
Openfda › Package ndc › 147781-640-90
Openfda › Package ndc › 247781-640-10
Openfda › Package ndc › 347781-643-90
Openfda › Package ndc › 447781-643-10
Openfda › Package ndc › 547781-646-90
Openfda › Package ndc › 647781-646-10
Openfda › Package ndc › 747781-649-90
Openfda › Package ndc › 847781-649-10
Openfda › Package ndc › 947781-651-90
Openfda › Package ndc › 1047781-651-10
Openfda › Package ndc › 1147781-654-90
Openfda › Package ndc › 1247781-654-10
Openfda › Package ndc › 1347781-657-90
Openfda › Package ndc › 1447781-657-10
Openfda › Package ndc › 1547781-659-90
Openfda › Package ndc › 1647781-659-10
Openfda › Package ndc › 1747781-662-90
Openfda › Package ndc › 1847781-662-10
Openfda › Package ndc › 1947781-665-90
Openfda › Package ndc › 2047781-665-10
Openfda › Package ndc › 2147781-668-90
Openfda › Package ndc › 2247781-668-10
Openfda › Package ndc › 2347781-671-90
Openfda › Package ndc › 2447781-671-10
Openfda › Product ndc › 147781-640
Openfda › Product ndc › 247781-643
Openfda › Product ndc › 347781-646
Openfda › Product ndc › 447781-649
Openfda › Product ndc › 547781-651
Openfda › Product ndc › 647781-654
Openfda › Product ndc › 747781-657
Openfda › Product ndc › 847781-659
Openfda › Product ndc › 947781-662
Openfda › Product ndc › 1047781-665
Openfda › Product ndc › 1147781-668
Openfda › Product ndc › 1247781-671
Openfda › Generic nameLEVOTHYROXINE SODIUM
Openfda › Product typeHUMAN PRESCRIPTION DRUG
Openfda › Substance nameLEVOTHYROXINE SODIUM
Openfda › Manufacturer nameAlvogen, Inc.
Openfda › Application numberNDA021116
Openfda › Is original packagertrue
Event id98225
Address 144 Whippany Rd Ste 300
Code infoLot # MHA21825, Exp Date: December 31, 2027
Postal code07960-4558
Report date20260121
Product typeDrugs
Reason for recallProduct Mix-Up: A single bottle of this lot was reported by a pharmacy to contain 88 mcg tablets instead of 150 mcg tablets.
Voluntary mandatedVoluntary: Firm initiated
Recall initiation date20251231
Initial firm notificationLetter
Center classification date20260114

Overview

  • Recalling FirmAlvogen, Inc
  • StatusOngoing
  • Risk LevelClass II
  • DistributionUS Nationwide.
Official Agency Alert

Related Recalls

Pharmaceutical
FDA DrugsClass II

Lacosamide Tablets, USP, C V, 100mg, Rx only, 60-count bottle, By: Annora Pharma...

Presence of a Foreign Tablets: Complaint received, possible mix-up of Selexipag 1000 mcg tablet in a bottle of Lacosamide Tablets USP, 100mg.

Jul 1, 2026Annora Pharma Private Limited
Pharmaceutical
FDA DrugsClass II

Corlanor (ivabradine) tablets, 5 mg, packaged in a) 14 tablets bottles (NDC 5551...

Presence of Foreign Substance.

Jul 1, 2026Amgen, Inc.
Pharmaceutical
FDA DrugsClass II

BD ChloraPrep Clear, (2% w/v chlorhexidine gluconate (CHG) and 70% v/v isopropyl...

Lack of Assurance of Sterility: Due to wrinkles in the paper lidding which may breach the seal area.

Jul 1, 2026CareFusion 213, LLC